MedWatch

Raising ambitions at Novo Nordisk an obvious move, says CEO

Novo Nordisk is growing fast, and its CEO is now directly indicating that new, more ambitious long-term goals will be implemented.

Photo: Valdemar Ren

Novo Nordisk's rapid growth has made company President and CEO Lars Fruergaard Jørgensen publically air thoughts of increasing the company's 2025 ambitions, which were set just 2 years ago.

This includes the firm's goals for its obesity business, which has received a boost with unprecedented demand for the weight loss drug Wegovy, and the enormous sales of the diabetes drug Ozempic have also brought Novo Nordisk considerably closer to reaching some of its big 2025 milestones.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs